⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6758324 | 1.00 | — | — | |
| SCHEMBL6758073 | 1.00 | — | — | |
| SCHEMBL2349266 | 0.87 | — | — | |
| SCHEMBL1935108 | 0.80 | ESR1 (0.42) | — | |
| SCHEMBL6825608 | 0.79 | ESR1 (0.31) | — | |
| SCHEMBL14370535 | 0.78 | — | — | |
| SCHEMBL10115680 | 0.76 | — | — | |
| SCHEMBL23344299 | 0.76 | — | — | |
| SCHEMBL19381563 | 0.76 | ESR1 (0.31) | — | |
| SCHEMBL6822238 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391802-B2 | Method of forming semicrystalline polyetherimide, and polyetherimide-containing composition | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2025-08-19 | — | — | US | disclosed |
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024023266-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230241050-A1 | APPLICATIONS OF HPK1 KINASE INHIBITOR IN PREVENTING AND/OR TREATING ANIMAL PATHOGEN INFECTION | Guangzhou Yufan Nantu Biotechnologies Co., Ltd (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012155066-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | WANG SHAOMENG (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | SANOFI (FR) | 2012-11-15 | — | — | US | disclosed |
| WO-2012065022-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-18 | — | — | WO | disclosed |
| US-8153626-B2 | Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2011127058-A2 | BIOMARKERS FOR MDM2 INHIBITORS FOR USE IN TREATING DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011060049-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |